Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Banco Santander S.A.

Banco Santander S.A. cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 75.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,013 shares of the medical research company’s stock after selling 28,255 shares during the period. Banco Santander S.A.’s holdings in Thermo Fisher Scientific were worth $2,636,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Nuveen Asset Management LLC increased its position in shares of Thermo Fisher Scientific by 10,824.0% during the second quarter. Nuveen Asset Management LLC now owns 1,928,966 shares of the medical research company’s stock valued at $566,498,000 after acquiring an additional 1,911,308 shares during the last quarter. Jennison Associates LLC increased its position in shares of Thermo Fisher Scientific by 2,589.9% during the second quarter. Jennison Associates LLC now owns 819,138 shares of the medical research company’s stock valued at $240,564,000 after acquiring an additional 788,686 shares during the last quarter. Putnam Investments LLC boosted its stake in shares of Thermo Fisher Scientific by 2,645.9% in the second quarter. Putnam Investments LLC now owns 720,795 shares of the medical research company’s stock valued at $211,683,000 after purchasing an additional 694,545 shares during the period. AQR Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 38.8% in the second quarter. AQR Capital Management LLC now owns 2,141,471 shares of the medical research company’s stock valued at $621,561,000 after purchasing an additional 598,230 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in shares of Thermo Fisher Scientific by 22.9% in the second quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock valued at $877,186,000 after purchasing an additional 555,802 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

In related news, CEO Marc N. Casper sold 47,729 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $295.88, for a total value of $14,122,056.52. Following the completion of the transaction, the chief executive officer now owns 328,960 shares in the company, valued at $97,332,684.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 2,271 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $298.00, for a total transaction of $676,758.00. Following the completion of the transaction, the chief executive officer now owns 283,502 shares of the company’s stock, valued at approximately $84,483,596. The disclosure for this sale can be found here. 0.45% of the stock is owned by insiders.

NYSE TMO opened at $300.02 on Thursday. The firm has a 50 day simple moving average of $290.19 and a 200-day simple moving average of $284.26. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.23 and a current ratio of 1.80. Thermo Fisher Scientific Inc. has a one year low of $208.34 and a one year high of $306.00. The firm has a market cap of $118.15 billion, a price-to-earnings ratio of 26.98, a PEG ratio of 1.91 and a beta of 1.14.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.88 by $0.06. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The company had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.19 billion. During the same quarter in the previous year, the firm earned $2.62 earnings per share. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Equities analysts predict that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase program on Friday, November 8th that permits the company to repurchase $2.50 million in shares. This repurchase authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Tuesday, December 17th will be paid a $0.19 dividend. The ex-dividend date of this dividend is Monday, December 16th. This represents a $0.76 dividend on an annualized basis and a yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio is currently 6.83%.

Several research analysts have recently commented on TMO shares. JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Robert W. Baird raised their price objective on shares of Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Credit Suisse Group reissued a “buy” rating and issued a $310.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Finally, Needham & Company LLC raised their price objective on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $314.45.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: What are benefits of a growth and income fund?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.